- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.06. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 16.06. | NLS Pharmaceutics Ltd.: NLS Pharmaceutics CEO Issues Letter to Shareholders | 762 | PR Newswire | ZURICH, June 16, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP), a Swiss clinical-stage biopharmaceutical company focused on developing innovative... ► Artikel lesen | |
| 06.06. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 21.05. | NLS Pharmaceutics präsentiert Mazindol-Studie auf ASCP-Tagung | 2 | Investing.com Deutsch | ||
| NLS PHARMACEUTICS Aktie jetzt für 0€ handeln | |||||
| 21.05. | NLS Pharmaceutics to present Mazindol study at ASCP Meeting | 2 | Investing.com | ||
| 16.05. | NLS Pharmaceutics Ltd. - 20-F, Annual and transition report of foreign private issuers | 1 | SEC Filings | ||
| 05.05. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 24.04. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 15.04. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 15.04. | NLS Pharmaceutics Ltd.: NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models | 228 | PR Newswire | Non-opioid, multi-mechanism profile positions Mazindol as a differentiated asset in addiction therapeutics
Favorable results support potential expansion into high-value... ► Artikel lesen | |
| 31.03. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 31.03. | NLS Pharmaceutics AG: NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement | 430 | ACCESS Newswire | The equity financing is at a 10% premium to the market share price1 ZÜRICH, SWITZERLAND / ACCESS Newswire / March 31, 2025 / NLS Pharmaceutics Ltd.(NASDAQ:NLSP) ("NLS" or the "Company"), a Swiss clinical-stage... ► Artikel lesen | |
| 10.03. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 10.03. | NLS Pharmaceutics kündigt Fusion mit Kadimastem an | 2 | Investing.com Deutsch | ||
| 27.02. | NLS Pharmaceutics reports progress in narcolepsy treatment | 1 | Investing.com | ||
| 27.02. | NLS Pharmaceutics Ltd.: NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform | 247 | PR Newswire | ZÜRICH, Switzerland, Feb. 27, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) (Nasdaq: NLSPW) ("NLS" or the "Company"), in collaboration with Aexon... ► Artikel lesen | |
| 25.02. | NLS Pharmaceutics Ltd.; Kadimastem Ltd.: Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment | 292 | PR Newswire | Companies Advance Collaborative Clinical Development of iTOL-102: A Potential Cure for Diabetes Without the Need for Chronic Life-long Immune Suppression ZURICH and NESS ZIONA, Israel... ► Artikel lesen | |
| 25.02. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 10.02. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 05.02. | NLS Pharmaceutics files to sell 645.2K shares for holders | 1 | Seeking Alpha |
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SOLID BIOSCIENCES | 4,720 | -1,87 % | Citi startet Berichterstattung für Solid Biosciences mit Kaufempfehlung | ||
| HARMONY BIOSCIENCES | 31,980 | +0,38 % | Mizuho reaffirms Harmony Biosciences stock rating on positive orexin data | ||
| CG ONCOLOGY | 25,950 | -0,46 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal... ► Artikel lesen | |
| QIAGEN | 41,000 | -0,56 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
| LYELL IMMUNOPHARMA | 8,940 | -1,97 % | Lyell Immunopharma, Inc. - 8-K, Current Report | ||
| SPRINGWORKS THERAPEUTICS | 46,990 | 0,00 % | SpringWorks Therapeutics, Inc. - 8-K, Current Report | ||
| KYMERA THERAPEUTICS | 44,080 | -3,57 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen | |
| CLIMB BIO | 1,180 | -5,60 % | Climb Bio, Inc.: Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer | Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll... ► Artikel lesen | |
| ADMA BIOLOGICS | 18,160 | -1,30 % | Will Strong Asceniv Sales Drive ADMA Biologics Further? | ||
| ALLOGENE THERAPEUTICS | 1,180 | -1,67 % | Allogene Therapeutics, Inc. - 8-K, Current Report | ||
| RECURSION PHARMACEUTICALS | 5,030 | -6,85 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
| EVOTEC | 7,138 | -0,81 % | Deutz Aktie: Vorsicht, es wird kritisch! - Dazu: Allianz, Evotec, Kontron, Mutares, TUI - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| BIONTECH | 90,70 | -0,60 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
| CARGO THERAPEUTICS | 4,190 | -0,71 % | Pre-market Movers: Leishen Energy, Black Diamond Therapeutics, FST Corp., 5E Advanced Materials, CARGO Therapeutics | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.00 A.M. ET).In the Green Leishen Energy Holding Co., Ltd. (LSE) is up over... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 20,610 | -3,33 % | H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target |
Das Unternehmen NLS PHARMACEUTICS LTD kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,220 (+8,66 %) liegt der Kurs bei 2,760 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NLS PHARMACEUTICS LTD finden Sie auf Wallstreet Online.